Literature DB >> 28517948

Randomized controlled trial of an internet cognitive behavioral skills-based program for auditory hallucinations in persons with psychosis.

Jennifer D Gottlieb1, Vasudha Gidugu1, Mihoko Maru1, Miriam C Tepper2, Matthew J Davis2, Jennifer Greenwold2, Ruth A Barron2, Brian P Chiko3, Kim T Mueser1.   

Abstract

OBJECTIVE: Despite strong evidence supporting the effectiveness of cognitive-behavioral therapy for psychosis (CBTp), most clinicians in the United States have received little or no training in the approach and access remains very low, indicating a potential role for technology in increasing access to this intervention. Coping With Voices (CWV) is a 10-session, interactive, Web-based CBTp skills program that was developed to meet this need, and was shown to be feasible and associated with reduced severity of auditory hallucinations in a previous pilot study. To more rigorously evaluate this program, a randomized controlled trial was conducted comparing the efficacy of CWV to usual care (UC).
METHOD: The trial was conducted with a sample of 37 community mental health center clients with schizophrenia and moderate-to-severe auditory hallucinations, with assessments conducted at baseline, posttreatment, and 3-month follow-up.
RESULTS: Engagement in and satisfaction with the CWV program were high. Both the CWV and UC groups improved comparably in severity of auditory hallucinations and other symptoms over the treatment and at follow-up. However, participants in the CWV program showed significantly greater increases in social functioning and in knowledge about CBTp. CONCLUSIONS AND IMPLICATIONS FOR PRACTICE: The results suggest that the CWV program has promise for increasing access to CBTp, and associated benefits in the management of distressing psychotic symptoms and improving social functioning. (PsycINFO Database Record (c) 2017 APA, all rights reserved).

Entities:  

Mesh:

Year:  2017        PMID: 28517948     DOI: 10.1037/prj0000258

Source DB:  PubMed          Journal:  Psychiatr Rehabil J        ISSN: 1095-158X


  6 in total

1.  Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta-analysis.

Authors:  Irene Bighelli; Georgia Salanti; Maximilian Huhn; Johannes Schneider-Thoma; Marc Krause; Cornelia Reitmeir; Sofia Wallis; Felicitas Schwermann; Gabi Pitschel-Walz; Corrado Barbui; Toshi A Furukawa; Stefan Leucht
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

Review 2.  Engagement with online psychosocial interventions for psychosis: A review and synthesis of relevant factors.

Authors:  Chelsea Arnold; John Farhall; Kristi-Ann Villagonzalo; Kriti Sharma; Neil Thomas
Journal:  Internet Interv       Date:  2021-06-05

Review 3.  The Effectiveness of Internet-Based Cognitive Behavioral Therapy in Treatment of Psychiatric Disorders.

Authors:  Vikram Kumar; Yasar Sattar; Anan Bseiso; Sara Khan; Ian H Rutkofsky
Journal:  Cureus       Date:  2017-08-29

4.  An internet-based intervention for people with psychosis (EviBaS): study protocol for a randomized controlled trial.

Authors:  Nina Rüegg; Steffen Moritz; Thomas Berger; Thies Lüdtke; Stefan Westermann
Journal:  BMC Psychiatry       Date:  2018-04-13       Impact factor: 3.630

Review 5.  Potential Applications of Digital Technology in Assessment, Treatment, and Self-help for Hallucinations.

Authors:  Neil Thomas; Josef J Bless; Ben Alderson-Day; Imogen H Bell; Matteo Cella; Tom Craig; Philippe Delespaul; Kenneth Hugdahl; Julien Laloyaux; Frank Larøi; Tania M Lincoln; Björn Schlier; Prabitha Urwyler; David van den Berg; Renaud Jardri
Journal:  Schizophr Bull       Date:  2019-02-01       Impact factor: 9.306

6.  Mindfulness Mediates the Effect of a Psychological Online Intervention for Psychosis on Self-Reported Hallucinations: A Secondary Analysis of Voice Hearers From the EviBaS Trial.

Authors:  Thies Lüdtke; Heike Platow-Kohlschein; Nina Rüegg; Thomas Berger; Steffen Moritz; Stefan Westermann
Journal:  Front Psychiatry       Date:  2020-04-03       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.